Attention-Bias Modification Treatment for PTSD
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/21/2016 |
| Start Date: | May 2013 |
| End Date: | July 2017 |
| Contact: | Mikael Rubin, MA |
| Email: | rubinmi@nyspi.colubmia.edu |
| Phone: | 646-774-8104 |
Emerging research implicates biased attention to threat in the pathophysiology of anxiety
disorders. Recent findings demonstrate significant associations between attention bias and
stress vulnerability. This work has motivated the development of a novel therapy,
attention-bias-modification treatment (ABMT). ABMT is designed to implicitly modify
patients' biased threat attendance via computerized training protocols. Emerging evidence
indicates that ABMT is effective in modifying threat-related attention biases and in
ameliorating anxiety symptoms. However, it is unclear whether ABMT is efficacious for
Posttraumatic stress disorder (PTSD). The present pilot study is a double blind trial that
seeks to examine feasibility, acceptability, safety, efficacy, and risk/benefit ratio of
ABMT in individuals with PTSD. In addition this pilot study seeks to identify specific genes
associated with anxiety disorders and to examine whether these can predict the success of
the ABMT.
disorders. Recent findings demonstrate significant associations between attention bias and
stress vulnerability. This work has motivated the development of a novel therapy,
attention-bias-modification treatment (ABMT). ABMT is designed to implicitly modify
patients' biased threat attendance via computerized training protocols. Emerging evidence
indicates that ABMT is effective in modifying threat-related attention biases and in
ameliorating anxiety symptoms. However, it is unclear whether ABMT is efficacious for
Posttraumatic stress disorder (PTSD). The present pilot study is a double blind trial that
seeks to examine feasibility, acceptability, safety, efficacy, and risk/benefit ratio of
ABMT in individuals with PTSD. In addition this pilot study seeks to identify specific genes
associated with anxiety disorders and to examine whether these can predict the success of
the ABMT.
ABMT is designed to implicitly modify patients' biased threat attendance via computerized
training protocols. Emerging evidence indicates that ABMT is effective in modifying
threat-related attention biases and in ameliorating anxiety symptoms.
training protocols. Emerging evidence indicates that ABMT is effective in modifying
threat-related attention biases and in ameliorating anxiety symptoms.
Inclusion Criteria:
- Males or females between the ages of 18 and 60;
- Current DSM-IV PTSD for the last 12 months or more;
- Fluent in English and willing and able to give informed written consent and
participate responsibly in the protocol;
- Attention bias toward or away from threat assessed by Dot-probe attention bias task
Exclusion Criteria:
- Current DSM-IV Axis I disorder other than PTSD.
- Patients with comorbid (i.e., secondary diagnosis of) major depressive disorder (MDD)
will be allowed for enrollment if their HAM-D score doesn't exceed 25;
- Prior or current diagnosis of schizophrenia, schizoaffective disorder, organic mental
disorder, bipolar disorder, or antisocial, schizotypal, and schizoid personality
disorders;
- Suicidal ideation or behavior that poses a significant danger to the subject.
Unstable clinical condition such that participation in a controlled trial would pose
a significant danger;
- Prior participation in attention bias modification treatment (ABMT);
- Current or past history of seizure disorder (except febrile seizure in childhood);
- Currently on psychotropic medication. (excluding the use of hypnotics);
- Currently participating in formal psychotherapy. This includes:
- psychodynamic,
- cognitive behavioral and interpersonal therapies
- Current unstable or untreated medical illness;
- Vision loss.
We found this trial at
1
site
1051 Riverside Dr
New York, New York 10032
New York, New York 10032
646-774-5000
Principal Investigator: Yuval Neria, PhD
Phone: 646-774-8104
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
